Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About this trial

The standard method for localizing non-palpable breast cancer is currently preoperative wire-guided localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of wire vs. combined breast tissue markers in localizing non-palpable breast cancer.

Eligibility criteria

Qualifiers

female patients, age≥18 year

A score of ≥ 2 on the Eastern Cooperative Oncology Group scale

Patients pathologically diagnosed with untreated breast cancer by core-needle biopsy, with histologically confirmed non-palpable in situ cancer, including pleomorphic lobular carcinoma in situ or invasive non-palpable breast cancer that required localization

Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery.

Disqualifiers

Inflammatory breast cancer or Paget's disease

Breast deformities and other conditions that impact breast conservation success rate

Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded

Pregnancy or lactation

Trial design

Treatments tested in this trial

  • Wire-guided localization and marker clip localization
  • Wire-guided localization

Treatment groups

170 Participants
are divided into 2 treatment groups